Alterity Therapeutics Limited (NASDAQ:ATHE – Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 90,300 shares, an increase of 290.9% from the March 31st total of 23,100 shares. Based on an average daily volume of 82,300 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.1% of the shares of the company are sold short.
Alterity Therapeutics Stock Up 11.1 %
Shares of NASDAQ ATHE traded up $0.25 during mid-day trading on Friday, hitting $2.51. The company had a trading volume of 87,873 shares, compared to its average volume of 176,674. Alterity Therapeutics has a 12 month low of $1.55 and a 12 month high of $5.41. The business’s 50-day simple moving average is $1.96 and its 200-day simple moving average is $2.18.
Analysts Set New Price Targets
Separately, Benchmark reiterated a “speculative buy” rating and set a $4.00 target price on shares of Alterity Therapeutics in a research note on Thursday, March 7th.
About Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.
Featured Articles
- Five stocks we like better than Alterity Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- MarketBeat Week in Review – 4/22 – 4/26
- Where to Find Earnings Call Transcripts
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Dogs of the Dow Strategy? Overview and Examples
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
